<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071963</url>
  </required_header>
  <id_info>
    <org_study_id>MDT16056</org_study_id>
    <nct_id>NCT05071963</nct_id>
  </id_info>
  <brief_title>INSPIRE Pipeline™ Shield Post Approval Study</brief_title>
  <official_title>Neurovascular Product Surveillance Registry (INSPIRE) Pipeline™ Flex Embolization Device With Shield Technology™ Post Approval Study (PAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Neurovascular Clinical Affairs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Neurovascular Clinical Affairs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval&#xD;
      Study (PAS) (&quot;Pipeline™ Shield PAS&quot;) is to collect on-label use data in patients undergoing&#xD;
      treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with&#xD;
      Shield Technology™ (&quot;Pipeline™ Shield Device&quot;) in a real-world post approval setting within&#xD;
      the United States.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The INSPIRE Pipeline™ Shield Post Approval Study is an observational, prospective,&#xD;
      multi-center, single-arm registry to collect on-label use data in patients undergoing&#xD;
      treatment for intracranial aneurysms using the Pipeline™ Flex Embolization Device with Shield&#xD;
      Technology™ according to the intended use.&#xD;
&#xD;
      The primary objective of this study is to evaluate the on-label use of the Pipeline™ Shield&#xD;
      Device in patients undergoing treatment for intracranial aneurysms per institutional routine&#xD;
      clinical care in a real-world post approval study setting in the U.S.&#xD;
&#xD;
      This study is conducted under the Product Surveillance Registry (NCT01524276) and is a&#xD;
      sub-study to the therapy specific Neurovascular Product Surveillance Registry (NCT02988128).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2021</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of the composite outcome (Occlusion of the target aneurysm, Significant parent artery stenosis, Retreatment of the target aneurysm) at 1 year post-procedure.</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence at 1-year post-procedure of complete occlusion of the target aneurysm, significant parent artery stenosis ≤ 50%, and no retreatment of the target aneurysm.</description>
  </primary_outcome>
  <enrollment type="Anticipated">203</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment of Intracranial Aneurysms</intervention_name>
    <description>Embolization of aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients requiring treatment for intracranial aneurysms with the market approved Pipeline™&#xD;
        Flex Embolization Device with Shield Technology™ device are eligible for the registry&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient or legally authorized representative (LAR) provides authorization and/or&#xD;
             consent per institution and geographical requirements.&#xD;
&#xD;
          2. Patient is intended to receive or be treated with an eligible Medtronic product.&#xD;
&#xD;
          3. Patient is consented within the enrollment window of the therapy received, as&#xD;
             applicable.&#xD;
&#xD;
          4. Patient or patient's legally authorized representative (LAR) has provided written&#xD;
             informed consent using the IRB and Medtronic approved Informed Consent Form and agrees&#xD;
             to comply with the study requirements. HIPAA/data protection authorization has been&#xD;
             provided and signed by the patient (or patient's LAR).&#xD;
&#xD;
          5. Patient has already been selected for endovascular treatment of the target aneurysm&#xD;
             with the Pipeline™ Shield Device as the appropriate treatment per the Pipeline™ Shield&#xD;
             Device Instructions For Use (IFU).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who is, or is expected to be, inaccessible for follow-up.&#xD;
&#xD;
          2. Participation is excluded by local law.&#xD;
&#xD;
          3. Patient is currently enrolled or plans to enroll in a concurrent drug/device study&#xD;
             that may confound the PSR results (i.e. no required intervention that could affect&#xD;
             interpretation of all-around product safety and/or effectiveness).&#xD;
&#xD;
          4. Female patient who is known to be pregnant or is breastfeeding or wishes to become&#xD;
             pregnant during participation in the study.&#xD;
&#xD;
          5. Patient is contraindicated for the device or procedure per the Pipeline™ Shield Device&#xD;
             IFU.&#xD;
&#xD;
          6. The Investigator determined that the health of the patient may be compromised by the&#xD;
             patient's enrollment.&#xD;
&#xD;
          7. Patient is enrolled or planning to participate in a potentially confounding drug or&#xD;
             device trial during the course of this study. Co-enrollment in concurrent trials is&#xD;
             only allowed when documented pre-approval was obtained from Medtronic.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Van Deman</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medtronic Neurovascular Clinical Affairs</last_name>
    <phone>949-837-3700</phone>
    <email>rs.shieldpostapproval@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Jones, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Matouk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Hanel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Grossberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Yao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-6402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Raz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabor Toth, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma (OU) University Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hakeem Shakir, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Jankowitz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethan Benardete, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>November 4, 2022</last_update_submitted>
  <last_update_submitted_qc>November 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

